AR101523A1 - Compuestos para el tratamiento de condiciones asociadas con la actividad de dgat1 - Google Patents
Compuestos para el tratamiento de condiciones asociadas con la actividad de dgat1Info
- Publication number
- AR101523A1 AR101523A1 ARP140100113A ARP140100113A AR101523A1 AR 101523 A1 AR101523 A1 AR 101523A1 AR P140100113 A ARP140100113 A AR P140100113A AR P140100113 A ARP140100113 A AR P140100113A AR 101523 A1 AR101523 A1 AR 101523A1
- Authority
- AR
- Argentina
- Prior art keywords
- treatment
- dgat1
- activity
- compounds
- conditions associated
- Prior art date
Links
- 102100036869 Diacylglycerol O-acyltransferase 1 Human genes 0.000 title abstract 2
- 101000927974 Homo sapiens Diacylglycerol O-acyltransferase 1 Proteins 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 abstract 6
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361751443P | 2013-01-11 | 2013-01-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR101523A1 true AR101523A1 (es) | 2016-12-28 |
Family
ID=50001335
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140100113A AR101523A1 (es) | 2013-01-11 | 2014-01-13 | Compuestos para el tratamiento de condiciones asociadas con la actividad de dgat1 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US8987459B2 (enExample) |
| EP (1) | EP2943488B1 (enExample) |
| JP (1) | JP6302937B2 (enExample) |
| KR (1) | KR20150103747A (enExample) |
| CN (1) | CN104995188B (enExample) |
| AR (1) | AR101523A1 (enExample) |
| AU (1) | AU2014205276B2 (enExample) |
| BR (1) | BR112015016370A2 (enExample) |
| CA (1) | CA2896861A1 (enExample) |
| EA (1) | EA027688B1 (enExample) |
| ES (1) | ES2675398T3 (enExample) |
| MX (1) | MX2015008978A (enExample) |
| PL (1) | PL2943488T3 (enExample) |
| PT (1) | PT2943488T (enExample) |
| TR (1) | TR201808198T4 (enExample) |
| WO (1) | WO2014110344A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104995188B (zh) * | 2013-01-11 | 2018-09-14 | 诺华股份有限公司 | 2-((1r,4r)-4-(4-(5-(苯并噁唑-2-基氨基)吡啶-2-基)苯基)环己基)乙酸的葡甲胺盐形式和它们作为dgat1抑制剂的用途 |
| KR101684053B1 (ko) * | 2015-01-20 | 2016-12-08 | 씨제이헬스케어 주식회사 | 벤즈이미다졸 유도체의 신규 결정형 및 이의 제조방법 |
| US10822346B2 (en) * | 2018-04-17 | 2020-11-03 | Cardurion Pharmaceuticals, Llc | Meglumine salts of thienopyrimidines |
| MX2023005447A (es) * | 2020-11-10 | 2023-09-25 | Unity Biotechnology Inc | Inhibidor de sales sólidas cristalinas de meglumina de bcl y métodos de elaboración y uso de estos. |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200303742A (en) | 2001-11-21 | 2003-09-16 | Novartis Ag | Organic compounds |
| PT2402319T (pt) * | 2006-03-31 | 2017-12-11 | Novartis Ag | Inibidores de dgat |
| WO2013169648A1 (en) * | 2012-05-07 | 2013-11-14 | Novartis Ag | Pharmaceutical combinations comprising a dgat1 inhibtor and a triglyceride lowering drug |
| CN104995188B (zh) * | 2013-01-11 | 2018-09-14 | 诺华股份有限公司 | 2-((1r,4r)-4-(4-(5-(苯并噁唑-2-基氨基)吡啶-2-基)苯基)环己基)乙酸的葡甲胺盐形式和它们作为dgat1抑制剂的用途 |
-
2014
- 2014-01-10 CN CN201480003867.0A patent/CN104995188B/zh not_active Expired - Fee Related
- 2014-01-10 PT PT147012736T patent/PT2943488T/pt unknown
- 2014-01-10 EA EA201591300A patent/EA027688B1/ru not_active IP Right Cessation
- 2014-01-10 PL PL14701273T patent/PL2943488T3/pl unknown
- 2014-01-10 US US14/152,282 patent/US8987459B2/en not_active Expired - Fee Related
- 2014-01-10 ES ES14701273.6T patent/ES2675398T3/es active Active
- 2014-01-10 JP JP2015552797A patent/JP6302937B2/ja not_active Expired - Fee Related
- 2014-01-10 CA CA2896861A patent/CA2896861A1/en not_active Abandoned
- 2014-01-10 WO PCT/US2014/011005 patent/WO2014110344A1/en not_active Ceased
- 2014-01-10 AU AU2014205276A patent/AU2014205276B2/en not_active Ceased
- 2014-01-10 MX MX2015008978A patent/MX2015008978A/es unknown
- 2014-01-10 KR KR1020157021323A patent/KR20150103747A/ko not_active Ceased
- 2014-01-10 TR TR2018/08198T patent/TR201808198T4/tr unknown
- 2014-01-10 BR BR112015016370A patent/BR112015016370A2/pt not_active IP Right Cessation
- 2014-01-10 EP EP14701273.6A patent/EP2943488B1/en not_active Not-in-force
- 2014-01-13 AR ARP140100113A patent/AR101523A1/es unknown
-
2015
- 2015-02-24 US US14/630,624 patent/US9242971B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| KR20150103747A (ko) | 2015-09-11 |
| CA2896861A1 (en) | 2014-07-17 |
| EA201591300A1 (ru) | 2015-11-30 |
| CN104995188B (zh) | 2018-09-14 |
| AU2014205276A1 (en) | 2015-07-16 |
| EP2943488A1 (en) | 2015-11-18 |
| MX2015008978A (es) | 2015-09-29 |
| WO2014110344A1 (en) | 2014-07-17 |
| AU2014205276B2 (en) | 2016-10-20 |
| CN104995188A (zh) | 2015-10-21 |
| ES2675398T3 (es) | 2018-07-11 |
| PL2943488T3 (pl) | 2018-09-28 |
| US8987459B2 (en) | 2015-03-24 |
| JP6302937B2 (ja) | 2018-03-28 |
| EA027688B1 (ru) | 2017-08-31 |
| PT2943488T (pt) | 2018-06-12 |
| EP2943488B1 (en) | 2018-03-28 |
| BR112015016370A2 (pt) | 2017-07-11 |
| JP2016505017A (ja) | 2016-02-18 |
| US20150166522A1 (en) | 2015-06-18 |
| US9242971B2 (en) | 2016-01-26 |
| TR201808198T4 (tr) | 2018-07-23 |
| US20140200246A1 (en) | 2014-07-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR089818A1 (es) | Inhibidor de la quinasa que regula la señal de la apoptosis | |
| JOP20210105B1 (ar) | مركبات وتركيبات لمعالجة حالات مرضية مرتبطة بنشاط nlrp | |
| HRP20181684T1 (hr) | Postupak primjene 4-((1r,3s)-6-klor-3-fenil-indan-1-il)-1,2,2-trimetil-piperazina i njegovih soli u liječenju shizofrenije | |
| CL2015003442A1 (es) | Derivados heterociclicos | |
| AR108768A2 (es) | Compuestos de piridina y pirazol y sus usos para la modulación de hemoglobina | |
| UA122781C2 (uk) | Пестицидно активні гетероциклічні похідні з сірковмісними замісниками | |
| CY1124088T1 (el) | Παραγωγα 2,4-θειαζολιδινεδιονης στη θεραπεια διαταραχων του κεντρικου νευρικου συστηματος | |
| HRP20180695T1 (hr) | Derivati benzamida za inhibiranje aktivnosti od abl1, abl2 i bcr-abl1 | |
| AR116394A2 (es) | Mesilato de n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)fenil]acetamida monohidrato | |
| MX2016012009A (es) | Nanoparticulas terapeuticas que comprenden un agente terapeutico, y metodos para su elaboracion y uso. | |
| MX381417B (es) | Inhibidores de glucosidasa. | |
| UY35998A (es) | 1-(3-(tert-BUTIL)1-(p-TOLIL)-1H-PIRAZOL-5-IL)-3-(4-((2-((6-ETILPIRAZIN-2-IL)AMINO)PIRIDIN-4-IL)METOXI)NAFTALEN-1-IL) UREA Y SUS SALES DERIVADAS FARMACÉUTICAMENTE ACEPTABLES, COMO INHIBIDORES DE P38 M AP QUINASA | |
| PT2987791T (pt) | Derivado de ácido 3-(4-(benziloxi)fenil)hex-4-inoico, adequado para prevenção e tratamento de doenças metabólicas. | |
| AR111469A1 (es) | Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma | |
| EA201691039A1 (ru) | Лечение гомозиготной семейной гиперхолестеринемии | |
| CL2016001095A1 (es) | Silicato de zirconio microporoso para el tratamiento de hipercalemia. | |
| CO2017003699A2 (es) | Compuesto heterocíclico | |
| DOP2012000058A (es) | Agente terapeutico para trastornos del estado de animo | |
| CO6710909A2 (es) | Nuevas formas cristalinas de la sal sódica del ácido (4-{4-[5-(6-trifluoro-metil-piridin-3-il-amino)-piridin-2-il]-fenil}-ciclohexil)-acético. | |
| MX374220B (es) | Nepentesina para usarse en el tratamiento de la intolerancia al gluten y padecimientos relacionados. | |
| EA201591300A1 (ru) | Формы меглуминовой соли 2-((1r,4r)-4-(4-(5-(бензоксазол-2-иламино)пиридин-2-ил)фенил)циклогексил)уксусной кислоты и их применение в качестве ингибиторов dgat1 | |
| CO6680652A2 (es) | Usos terapéuticos de 1-[2-(2.4-dimetil-fenilsulfanil)fenil]piperazina | |
| DOP2012000056A (es) | Agente terapeutico para trastornos de ansiedad | |
| CL2017001478A1 (es) | Combinación de un derivado de 6-oxo-1,6-dihidro-piridazina que tiene actividad anti-cáncer con un inhibidor de factor de crecimiento epidérmico (egfr) | |
| MX370061B (es) | Uso de antagonistas del par-1 para prevenir y/o tratar condiciones patologicas funcionales pelviperineales. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |